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license (http://creativelatent dementia phenotype, “d”. Both associations may be specific to non-Hispanic whites (NHW),
not Mexican-Americans (MA). In this analysis, we examine ethnicity’s effect on THPO’s association
with change in d scores, in the Texas Alzheimer’s Research and Care Consortium (TARCC).
Methods: We constructed an ethnicity equivalent d homolog (“dEQ”) among n 5 1113 MA and
n5 1958 NHW. dEQ was output as a composite “dEQ-score” for each of five annual TARCC waves.
Those composites were used as indicators of a latent growth curve (LGC). The mean dEQ intercept
(idEQ) and slope (DdEQ) were estimated in a random subset of N5 1528 participants and replicated
in the remainder (n 5 1544). THPO was regressed onto idEQ and DdEQ. Those associations were
tested separately in MA and NHW.
Results: dEQ correlated strongly with CDR-SB (r5 0.99,P, .001) and achieved high AUCs for AD
diagnosis at each wave (range 5 0.95–0.99). THPO was significantly associated with idEQ but not
DdEQ. That effect was observed in NHWonly. InMA, THPO had no associations with either idEQ or
DdEQ.
Discussion: We confirm THPO’s ethnicity-specific association with d in NHW. It is further clarified
that this association is specific to d’s intercept and not its slope. This analysis provides a model for
how dementia’s specific serum biomarkers can be characterized.
 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Aging; Cognition; Dementia; Functional status; Intelligence; THPO1. Introduction
We have recently constructed a latent phenotype for de-
mentia itself, as distinct from cognitive performance per se
[1]. Our approach uses a novel confirmatory bifactor model
in a structural equation model framework. Compared to
observed measures, the latent variable “d” (for dementia)uthor. Tel.: 11-210-567-1255; Fax: 11-210-567-
yall@uthscsa.edu
16/j.dadm.2016.02.003
he Authors. Published by Elsevier Inc. on behalf of the Alzhe
commons.org/licenses/by-nc-nd/4.0/).is relatively free of demographic measurement bias,
continuously distributed and appears to be “indifferent” to
its cognitive indicators [2].
d’s indifference to its indicators suggests that it can be
modeled in virtually any cognitive battery. We have demon-
strated this down to the level of individual items [3]. Thus,
we further distinguish between d, that is, “the cognitive cor-
relates of functional status”, and “d,” that is, d’s reification
as a composite score in any specific cognitive battery.
Across multiple batteries, these results in a set of d homo-
logs, all of which appear to share a similar psychometric
profile.imer’s Association. This is an open access article under the CC BY-NC-ND
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associated with Alzheimer’s Disease (AD) neuropathology
[4], AD-specific CSF biomarkers [5], certain serum inflam-
matory proteins [6], baseline, prospective change, and future
CDR scores [7,8].
We recently demonstrated significant associations be-
tween d and 10 serum proteins in the Texas Alzheimer’s
Research and Care Consortium (TARCC). They included
thrombopoietin (THPO), platelet-derived growth factor,
thrombospondin-1 (THBS1), and von-Willebrand factor
[6]. THPO was the strongest. Its effect was comparable to
education and APOE 34, and stronger than age, yet indepen-
dent of both. THPO was also the strongest predictor of clin-
ical AD in O’Bryant et al.’s 2011 study [9]. That association
was specific to AD in non-Hispanic whites (NHW) [10] but
not in Mexican-Americans (MA) [11]. Similarly, THPO’s
association with d scores was limited to NHW [6].
THPO regulates the proliferation and maturation of
megakaryocytes and platelet production. However, d is not
related to vasculopathy-related biomarkers such as vascular
cell adhesion molecule type 1 (VCAM-1), vascular endothe-
lial growth factor, or homocysteine (HCY), nor is it associ-
ated with ischemic pathology (at autopsy) in the National
Alzheimer’s Coordinating Center [7]. Regardless, platelets
have recently been recognized to contribute to innate immu-
nity [12]. d’s serum biomarkers, in their aggregate, suggest
that innate immunologic processes may be responsible for
dementia severity as measured by d [6].
The analyses to date have been cross sectional. However,
d’s intercept and slope are independently associated with de-
mentia severity, and d’s change over time is strongly related
to change in dementia severity [7,8]. It remains to be
determined whether THPO is associated with d’s slope,
and whether their association remains specific to NHW in
TARCC’s rapidly expanding cohort.2. Methods
2.1. Subjects
Subjects included n 5 3072 TARCC participants: 1182
cases of AD, 611 “mild cognitive impairment” (MCI) cases,
and 1276 controls. Each underwent serial annual standard-
ized clinical examinations. Institutional review board
approval was obtained at each site, and written informed
consent was obtained from all participants.
2.2. d’s indicators
All tests were available in Spanish translation.
Logical memory II: [13] After a 30-minute delay, the sub-
ject recalls two paragraphs read aloud.
Visual reproduction I: [13] The subject immediately re-
produces a set of figures after a brief exposure.
The Controlled Oral Word Association (COWA): [14]
The patient is asked to name as many words as they can in
1 minute, beginning with a certain letter.Digit Span Test (DST): [13] The DST sums the longest
set of numbers that the subject can immediately recall in cor-
rect order (forward and backward).
Instrumental activities of daily living (IADL): [15]
IADL’s were assessed using informant ratings. Functional
abilities were rated on a Likert scale ranging from 0 (no
impairment) to 3 (specific incapacity). A total IADL score
calculated as the sum of all eight items.2.3. Clinical covariates
Education: Education was coded continuously as years of
formal education.
Ethnicity: Ethnicity was determined by self-report and
coded dichotomously as “Hispanic” and “non-Hispanic”.
Gender: Gender was coded dichotomously.2.4. Clinical correlates
The Clinical Dementia Rating Scale sum of boxes
(CDR): [16] The CDR estimates dementia severity. A clini-
cian rates the participant on six domains—memory, orienta-
tion, judgment and problem solving, community affairs,
home, and hobbies and personal care. Each is rated on a scale
of 0.0–3.0. A total CDR “sum of boxes” (CDR-SB) score is
summed across all domains.2.5. Biomarkers
TARCC’s methodology has been described elsewhere
[17]. Briefly, nonfasting blood samples were collected in
serum-separating tubes, allowed to clot at room temperature
for 30 minutes, centrifuged, aliquoted, and stored at 280C
in plastic vials. Serum samples were sent frozen to rules-
based medicine (RBM) (http://www.rulesbasedmedicine.
com/) in Austin, TX. There, they were assayed without addi-
tional freeze-thaw cycles. RBM conducted multiplexed
immunoassay via their human multianalyte profile (human
MAP).3. Statistical analyses
3.1. Analysis sequence
Data were inspected for normality and outliers (e.g.,
values .3 standard deviations) using univariate kurtosis
and skewness statistics. Multicolinearity was assessed by
noting the correlation among observed variables and the
variance inflation factor (VIF) [18]. Multivariate normality
in the structural models was assessed using Mardias coeffi-
cient [19].
The structural models were performed using Analysis of
Moment Structures (AMOS) software [20]. The maximum
likelihood estimator was chosen. Observed indicators were
adjusted for age, education, ethnicity, and gender. The resid-
ual covariances between these variables were estimated if
they were significant and improved fit.
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fects. Therefore, THPO’s associations with latent variables
were adjusted for dichotomous dummy variables coding batch.
We began with the confirmatory bifactor model published
in Royall & Palmer [6] [i.e., d(5)]. However, we used a
newer instance of TARCC’s data set (circa 2015). The
d(5) model necessitated additional modifications to regain
factor equivalence.
We began by stratifying the sample on ethnicity: Hispanic
MA (n 5 1113) and NHW (n 5 1958). Then, we tested the
evolving d homolog’s cross ethnic factor equivalence, one in-
dicator at a time, by comparingc2 fit in constrained versus un-
constrained models. Similarly, we examined group invariance
of the residual variances of each indicator. We examined d’s
indicators in the alphabetical sequence presented in
Supplementary Fig. 1. Each consecutive nonsignificant
constraint was held equal across groups in subsequentmodels.
If a cognitive performance indicator was significantly affected
by ethnicity, a replacement was chosen. The Wechsler Mem-
ory Scale Logical Memory I was replaced by LMII [13]. This
became a new ethnicity equivalent d homolog, “dEQ”.
The latent variable dEQ was re-validated by its associa-
tion with observed CDR-SB.We then tested dEQ’s factor de-
terminancy [21]. Next, we output the cross-ethnic
constrained dEQ factor scores as new composite variables
in each of five annual TARCC waves. These dEQ compos-
ites were each re-validated by ROC in the entire sample.
Finally, histograms of dEQ scores were generated in each
wave to confirm their distributions.
Thus, although dEQ was developed in an ethnicity strat-
ified sample, its indicator loadings were engineered to be sta-
tistically indiscriminable across ethnicity and after that was
achieved, the constrained loadings were used to generate a
single d-score composite, which was applied to all partici-
pants regardless of ethnicity and at every wave.
Next, we re-divided the combined sample on the basis of
a random split, into two similarly sized subgroups (groups 1
and 2). These groups were ethnically diverse. In group 1
(n 5 1528), we constructed a latent growth curve (LGC)
model using composite dEQ scores as its indicators (simi-
larly to Gavett et al.) [7]. In the LGC, the dEQ composite in-
dicators were adjusted for age, gender, and education. The
wave 4 slope parameter was allowed to vary freely, to
improve fit to nonlinear change. This resulted in two new
latent variables: dEQ’s intercept (idEQ) and 4-year slope
(DdEQ). DdEQ was additionally adjusted for idEQ.
Next, we tested wave 1 serum THPO’s associations idEQ
and DdEQ, by multivariate regression. Significant associa-
tions were replicated in group 2 (n5 1544). Next, we tested
THPO’s association with idEQ and DdEQ in each ethnic
subset separately (Hispanic: n 5 1113; NHW: n 5 1958).3.2. Missing data
Some variables (e.g., VRI) were not used at all sites in the
TARCC’s first wave. In addition, biomarker data from batch1 (n5 198) were excluded after it was discovered that serial
analyses of selected RBM analytes could not be replicated in
some cases. This left 888 subjects with complete biomarker
data. In contrast, psychometrics and adjudicated clinical di-
agnoses were available on 3072 subjects, only 2113 of whom
had complete data. Rather than using case-wise deletion, the
missing biomarker and psychometric data were handled by
full-information maximum likelihood (FIML) methods to
address missing data in the AMOS software.
In contrast to list-wise or pair-wise deletion, FIML yields
unbiased parameter estimates, preserves the overall power of
the analysis, and is arguably superior to alternative methods,
for example, multiple imputation [22–24] under
assumptions of ignorable missing data patterns (e.g.,
missing at random [MAR]). We assert that the missing
data pattern in this study is MAR due to the fact that
missingness was, for the most part, due to study design
rather than the inherent properties of the variables that are
missing. Furthermore, the multiple covariates added to the
model contribute to the assumption of MAR. Only the
ROC analyses, performed in Statistical Package for the
Social Sciences (SPSS) [25], were limited to complete cases.3.3. Factor determinancy
One potential limitation to the common factor model is
that an infinite number of unique factor score composites
can be derived from any factor [21]. These can be divided
into “determinant” and “indeterminant” fractions [26].
Several statistical methods are available to test determinacy.
We used Grice’s “Refined Factor Score Evaluation Program
(equation 5)” [21]. This method maximizes composite valid-
ity and is recommended when the factor composite scores
are to be used as “observed” variables in subsequent ana-
lyses (i.e., as LGC indicators). We report two indices from
this program’s output: “total item squared multiple correla-
tion” (TIMSC), and a “minimum correlation” (MC). Accept-
able TIMSC and MC should be .0.50.3.4. Fit indices
Fit was assessed using four common test statistics: chi-
square, the ratio of the chi-square to the degrees of freedom
in the model (CMIN/DF), the comparative fit index (CFI),
and the root mean square error of approximation (RMSEA).
A nonsignificant chi-square signifies that the data are consis-
tent with the model [27]. However, in large samples, these
metric conflicts with other fit indices (insensitive to sample
size) show that the model fits the data very well. ACMIN/DF
ratio,5.0 suggests an adequate fit to the data [28]. The CFI
statistic compares the specified model with a null model
[29]. CFI values range from 0 to 1.0. Values ,0.95 suggest
model misspecification. Values approaching 1.0 indicate
adequate to excellent fit. An RMSEA of 0.05 indicates a
close fit to the data, with models ,0.05 considered “good”
fit, and up to 0.08 as “acceptable” [30]. All fit statistics
Table 1
Descriptive statistics (analysis of variance)
Variable N Total sample
Post hoc tests
Main effect, P
AD, N 5 1182,
Mean (SD)
MCI, N 5 611,
Mean (SD)
Controls, N 5 1276,
Mean (SD)
Gender (% female) 3071 61.0 56.0* 56.0* 68.0yz ,.001
Ethnicity (% Hispanic) 3071 36.0 14.0 47.0y 52.0y ,.001
Age at visit 3072 70.9 (4.3) 75.5 (8.4)*z 71.6 (8.7)*y 66.3 (9.1)yz ,.001
Education 3072 13.2 (4.3) 14.0 (3.7)* 12.6 (4.3) 12.8 (4.7)y .004
CDR (sum of boxes) 3066 2.5 (3.4) 5.8 (3.4)*z 1.2 (0.9)*y 0.0 (0.1)yz ,.001
GDS (30 item) 2765 5.6 (5.3) 6.0 (5.1)* 7.1 (5.9)* 4.6 (4.8)yz ,.001
COWA 2982 8.4 (3.6) 7.3 (3.4)*z 8.2 (3.2)*y 9.5 (3.5)yz ,.001
WMS LM II 2529 8.2 (4.6) 3.7 (2.4)*z 8.3 (3.4)*y 11.7 (3.0)yz ,.001
WMS VR I 2480 8.1 (4.0) 5.4 (3.0)*z 87.8 (3.4)*y 9.9 (3.5)yz ,.001
DIS 2915 8.8 (3.1) 8.2 (3.0)* 8.6 (2.8)* 9.4 (3.2)yz ,.001
IADL (summed) 2556 10.1 (4.8) 14.9 (6.1)*z 8.4 (2.1)y 7.9 (1.0)y ,.001
Complete cases 2113
Abbreviations: CDR, Clinical Dementia Rating scale; COWA, Controlled Oral Word Association Test; DIS, Digit Span Test; GDS, Geriatric Depression
Scale; IADL, instrumental activities of daily living; MMSE, mini-mental state examination; SD, standard deviation; WMS LM II, Weschler Memory Scale:
Delayed Logical Memory; WMS VR II, Weschler Memory Scale: Delayed Visual Reproduction.
*P , .05 versus controls by Tukey’s HSD for unequal n’s.
yP , .05 versus AD by Tukey’s HSD for unequal n’s.
zP , .05 versus MCI by Tukey’s HSD for unequal n’s.
Table 2
Selected model “g” parameters in combined sample
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equacy of the models to the data.
3.5. Receiver-operating characteristic curves
A test’s diagnostic accuracy can be evaluated by ROC
[31]. Briefly, the true-positive rate (sensitivity) is plotted
as a function of the false-positive rate (100 2 specificity)
for different cut-off scores. Each point of the ROC curve rep-
resents a sensitivity or specificity dyad. The area under the
ROC curve (AUC) is a measure of how well a parameter
can distinguish between two diagnostic groups. We distin-
guished “AD” versus NC. ROC analyses were performed
in SPSS.Indicators Factor b S.E. Beta P value
DIS g’ 1 0.62
WMS LM II g’ 0.83 0.08 0.32 ,.001
WMS VR I g’ 0.89 0.07 0.40 ,.001
COWA g’ 1.17 0.07 0.64 ,.001
DIS dEQ 20.25 0.02 20.37 ,.001
WMS LM II dEQ 20.61 0.04 20.58 ,.001
WMS VR I dEQ 20.48 0.03 20.52 ,.001
COWA dEQ 20.34 0.03 20.45 ,.001
IADL dEQ 1 0.89 ,.001
Fit indices
X2(df) 181.0 (24)
X2/DF 7.54, P , .001
CFI 0.967
RMSEA 0.046
Abbreviations: CFI, comparative fit index; COWA, Controlled Oral Word
Association Test; DF, degrees of freedom; DST, Digit Span Test; IADL,
Instrumental Activities of Daily Living; RMSEA, Root Mean Square Error
of Association; S.E., Standard Error;WMS LM II,Weschler Memory Scale:
Delayed LogicalMemory;WMSVR I,WeschlerMemory Scale: Immediate
Visual Reproduction.4. Results
Descriptive statistics are listed in Table 1. Although there
are notable differences between diagnostic groups, no
extreme outliers were detected. After log transformation of
IADL, all variables displayed reasonably normal distribu-
tions (e.g., Kurtosis and skewness ,2). Supplementary
Table 1 presents dEQ’s incremental c2 change over increas-
ingly constrained models. The sequence tested is presented
in Supplementary Fig. 1. dEQ’s final model fit well (c2/
df 5 181/24, P , .001; CFI 5 0.97; RMSEA 5 0.05).
dEQ achieved cross-ethnic invariance with regard to all indi-
cator loadings and partial invariance of the residual vari-
ances (all indictors except IADL). Mean and variance
equivalence could not be achieved because of the differences
in the cross-ethnic distribution of TARCC diagnoses
(Table 1). There was no evidence of multicollinearity among
these variables as the inter-item correlations ranged from
0.29 to 0.57. In separate regression equations, the VIF wasassessed for each combination of the five variables used in
the latent variable model. There was no evidence of VIF
significantly .1.0.
The new latent variable “dEQ” is presented in
Supplementary Fig. 1. Our bifactor model results in two
latent variables, dEQ, and “g’”, which is d’s residual in
Spearman’s general intelligence factor “g” [1]. Both vari-
ables’ indicator loadings (for the combined sample) are
listed in Table 2 dEQ was strongly associated with IADL
(r 5 0.89, P , .001). g’ had no association with IADL (by
Table 3
LGC parameters in group 1 (N 5 1528)
Indicators Factor b S.E. Beta P value
dEQ1 idEQ 1 0.77
dEQ2 idEQ’ 1 0.71
dEQ3 idEQ 1 0.60
dEQ4 idEQ 1 0.51
dEQ5 idEQ 1 0.48
dEQ1 DdEQ 0 0.37
dEQ2 DdEQ 1 0.23
dEQ3 DdEQ 2 0.39
dEQ4 DdEQ 3 0.50
dEQ5 DdEQ 3.35 0.08 0.52 ,.001
Fit indices
X2(df) 422.2 (24)
X2/DF 10.05, P , .001
CFI 0.973
RMSEA 0.054
Abbreviations: CFI, comparative fit index; DF, degrees of freedom;
RMSEA, root mean square error of association; SE, standard error.
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CDR-SB (r 5 0.99, P , .001). Mardia’s coefficient in this
model was 2.37, indicating adequate multivariate normality.
As a check on the adequacy of our missing data assumptions,
the same model was run using complete data (n 5 888).
Although fit was slightly poorer, there were no statistically
significant differences in the obtained parameter estimates.
dEQ exhibited acceptable factor determinancy (i.e.,
TISMC 5 0.89; MC 5 0.59). We therefore output its factor
scores at each wave as a set of composite variables. These
achieved high AUCs (Supplementary Table 2). dEQ’s distri-
bution was increasingly bimodal over time (Fig. 1). Fig. 1
suggests a rightward (dementing) shift in the dEQ scores
in a subset of TARCC’s sample. As d is a strong predictor
of MCI conversion [5], this may reflect conversions to
dementia among initially nondemented subjects (i.e., at
lower baseline dEQ scores).
The dEQ composites were submitted to LGC as described
above. DdEQ’s model fit well (c2/df 5 422.2/24, P , .001;Fig. 1. dEQ histograms for selected waves (dEQ scores are referenced to the entire
dEQ scores.CFI5 0.97; RMSEA5 0.05). Note that the freely estimated
factor loading on the last measurement occasion of the
growth factor reveals that the true trajectory of DdEQ is
not quite linear but reflects a gradual leveling off after four
measurement occasion. This model resulted in two latent
variables, idEQ and DdEQ. Both latent variables’ indicator
loadings (in group 1) are presented in Table 3. idEQ was
strongly associated with DdEQ (r 5 0.77, P  .001).
In the final MIMICmodel is presented in Fig. 2. Random
subset group 1’s parameters are presented, and so the pre-
sented structural associations include subjects of both eth-
nicities. THPO was significantly associated with idEQ
(r 5 0.40, P , .001) but not DdEQ (r 5 20.15,
P 5 .175). The model’s fit was not significantly altered
when THPO’s associations with idEQ and DdEQ, and
idEQ’s association with DdEQ was constrained to be equal
across the two random subgroups [c2 5 422.2(24) vs
427(47); Difference5 4.8 (23), P. .99]. Thus dEQ’s inter-
cept, its slope, their association with each other, and
THPO’s associations with idEQ, all replicated across sub-
samples.
The sample was then stratified on ethnicity instead, to test
for cross-ethnic differences in dEQ’s temporal evolution
and/or THPO’s association with the LGC. The ethnicity
stratified model fits well (c2/df 5 367.6/44, P , .001;
CFI 5 0.97; RMSEA 5 0.05). Its fit was not significantly
altered when idEQ and DdEQ’s means were constrained to
be equal across ethnicity [c2 5 365.2(42) vs 367.6(44);
Difference 5 2.4(2), P . .25]. Thus, there are no cross-
group differences in either dEQ’s intercept or longitudinal
rate of change.
THPO remained significantly associated with idEQ in
NHW but was not significantly associated with either
idEQ or DdEQ in MA (Table 4). These results are consistent
with the observed nonlinear and ethnicity-specific trends in
serum THPO levels as a function of categorical diagnosis
(Supplementary Fig. 2). This figure and Table 4 reveal that
THPO’s relationship with idEQ in the random split
(Fig. 2) is driven by NHW only.cohort’s standardized mean [i.e., dEQ5 0.0]). NOTE. Rightward increase in
Fig. 2. THPO predicts dEQ’s intercept but not its slope (group 1 loadings.
Standardized parameter estimates. dEQ indicators are adjusted for age,
gender, and education [but not ethnicity]).
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We have confirmed an ethnicity-specific association be-
tween serum THPO levels and d. This analysis extends our
finding to longitudinal data and further clarifies their associ-
ation by restricting it to d’s intercept in NHW and not its
slope. No association was found between THPO and either
parameter in MA.
This suggests that THPO may be a “trigger” of one or
more dementing processes (in NHW) but may not
contribute significantly to dementia’s evolution over time.
That insight suggests THPO’s potential role in the transi-
tion from normal cognition to MCI. Supplementary Fig. 2Table 4
THPO’s Associations with dEQ intercept (idEQ) and slope (DdEQ) over
five waves in TARCC, stratified by ethnicity
Association
Hispanics (n 5 1113) NHW (N 5 1958)
Beta P value Beta P value
THPO . idEQ 0.106 .097 0.350 ,.001
THPO . DdEQ 20.095 .238 20.066 .546
NOTE. Standardized regression estimates, adjusted for batch effects and
idEQ (DdEQ).suggests that THPO levels differ most between NC and
MCI (in NHW), then return toward the mean of NC as
MCI progresses to AD. This hypothesis would require lon-
gitudinal biomarker data to confirm. Similar nonlinear
trends have been reported for other blood-based AD-related
biomarkers [32]. A nonlinear relationship between serum
biomarker levels, and d scores poses an obstacle to the iden-
tification of dementia-related biomarkers by categorical
contrasts (i.e., AD vs NC).
The present analysis offers a model for how dementia’s
specific serum biomarkers can be characterized. It can easily
be applied to each of TARCC’s remaining serum proteins, to
examine their potential associations with dEQ’s intercept
and longitudinal course, in either NHA or MA. We and
others, in different cohorts and by different methods, have
shown that change in d is strongly associated with change
in dementia severity, as measured by CDR [7,8].
Additionally, Koppara et al. [5] have shown that d homologs
outperform the ADAS-COG and CERAD as predictors of
MCI’s conversion to AD over 3 years. Thus, THPO’s associ-
ation with dEQ’s intercept in NHW is likely to be clinically
salient and may offer a target for clinical intervention at
AD’s very inception.
THPO is approved by the Food and Drug Administration
(FDA) for the treatment of thrombocytopenia, as are two
THPO receptor agonists, romiplostim (Nplate; Amgen
GmbH, Munich, Germany) and eltrombopag (Revolade,
Promacta; GlaxoSmithKline GmbH, Munich, Germany).
However, THPO’s association with idEQ is positive,
whereas dEQ’s cognitive loadings are inverse. Thus, expo-
sure to THPO or its agonists might undermine cognitive per-
formance through idEQ. Moreover, as idEQ is strongly
associated withDdEQ, THPO exposure might influence pro-
spective cognitive declines.
Cognitive deficits are not frequently reported as side-
effects of TPO and its agonists, but an effect on d could
easily be missed in raw performance data, especially in the
context of systemic illness. However, “intellectual
disability” (ID) has been associated with a mutation in the
methyltransferase-like 23 gene (METTL23), an upstream
modulator of THPO transcription. Overexpression of
THPO appears to mediate the association between
METTL23 and ID [33].
d has been shown to be “agnostic” to dementia’s etiology
[7]. Although TARCC is likely to be highly enriched with
AD cases, an estimated 20% of cases diagnosed with clinical
“AD” by experienced clinicians may be without beta-
amyloid by PiBPET [34]. Therefore, although TARCC pur-
ports to be a study of AD, dEQ’s intercept and slope may yet
be influenced additional dementing processes afflicting this
cohort. As there is significant variability about THPO’s asso-
ciation with idEQ (in NHW), THPO may not contribute to
them all.
Although d’s ethnicity-specific biomarkers suggest bio-
logical heterogeneity within the demented fraction of
TARCC participants, it should be recognized that Hispanic
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d scores, either at a clinical diagnosis of “AD” or at the stage
of MCI [6]. We have now shown that MA and NHW do not
differ in their rates of change in dEQ scores over time. This
suggests that the dementing processes afflicting Hispanic
and NHW TARCC participants has a similar natural history
in both groups.
Regardless, almost all the biomarkers that we have asso-
ciated with d to date have been specific to NHW. This result
is consistent with a growing literature of ethnicity-specific
AD biomarkers [10,35,36]. Additional analyses may
identify MA-specific d-related biomarkers and/or the bio-
markers ofDdEQ. Such analyses have the potential to distin-
guish the biological processes that initiate and maintain
dementing processes over time, and the populations within
which they operate. That understanding could better match
future treatments to AD’s natural history in individual
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1. Systematic review: d has only recently been
described, and its literature is rapidly evolving. All
relevant citations have been appropriately cited.
2. Interpretation: Our findings confirm THPO’s
ethnicity-specific association with dementia. It is
further clarified that this association is specific to d’s
intercept and not its slope.
3. Future directions: This analysis strengthens the case
for THPO as a target for dementia-specific inter-
vention in NHW. It suggests that such interventions
may have to be applied early in dementia’s evolution
to be effective. Furthermore, it provides a model for
how dementia’s specific serum biomarkers can be
characterized.
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